Evidence map›Paper›PMID 37455307›Full record

ArticleBiomarker research2023

MRI-based radiomic prognostic signature for locally advanced oral cavity squamous cell carcinoma: development, testing and comparison with genomic prognostic signatures.

Anna Corti, Loris De Cecco, Stefano Cavalieri, Deborah Lenoci, Federico Pistore, Giuseppina Calareso, Davide Mattavelli, Pim de Graaf, C René Leemans, Ruud H Brakenhoff and 5 more

Open access · goldAbstract read
In one paragraph

Article in Biomarker research, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 16 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
16citing papers in PubMed, 1 pooled it
3.7field-weighted citation impact, top 7% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

16 citing papers in PubMed, 1 synthesis or guideline pooled it, 16 citations in OpenAlex.

  1. Pooled it
  2. Article
  3. Article
  4. Article
  5. Article
  6. Article
  7. Article
  8. Prediction of bone invasion of oral squamous cell carcinoma using a magnetic resonance imaging-based machine learning model.European archives of oto-rhino-laryngology : official journal of the European Federation of Oto-Rhino-Laryngological Societies (EUFOS) : affiliated with the German Society for Oto-Rhino-Laryngology - Head and Neck Surgery · 2024
    Article
  9. Article
  10. Article
  11. Article
  12. Article
  13. Article
  14. Article
  15. Article
  16. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

15 authors at 6 institutions in 2 countries.

Anna CortiDepartment of Electronics, Information and Bioengineering, Politecnico di Milano, Milan, Italy. anna.corti@polimi.it.
Loris De CeccoIntegrated Biology of Rare Tumors, Department of Research, Fondazione IRCCS, Istituto Nazionale dei Tumori, Milan, Italy.
Stefano CavalieriHead and Neck Medical Oncology Department, Fondazione IRCCS, Istituto Nazionale dei Tumori, Milan, Italy.
Deborah LenociIntegrated Biology of Rare Tumors, Department of Research, Fondazione IRCCS, Istituto Nazionale dei Tumori, Milan, Italy.
Federico PistoreHead and Neck Medical Oncology Department, Fondazione IRCCS, Istituto Nazionale dei Tumori, Milan, Italy.
Giuseppina CalaresoRadiology Department, Fondazione IRCCS, Istituto Nazionale dei Tumori, Milan, Italy.
Davide MattavelliUnit of Otorhinolaryngology-Head and Neck Surgery, Department of Medical and Surgical Specialties, Radiological Sciences, and Public Health, ASST Spedali Civili of Brescia, University of Brescia, Brescia, Italy.
Pim de GraafAmsterdam UMC location Vrije Universiteit, Radiology and Nuclear Medicine, de Boelelaan 1117, Amsterdam, The Netherlands.
C René LeemansCancer Center Amsterdam, Imaging and Biomarkers, Amsterdam, The Netherlands.
Ruud H BrakenhoffCancer Center Amsterdam, Imaging and Biomarkers, Amsterdam, The Netherlands.
Marco RavanelliUnit of Radiology, Department of Medical and Surgical Specialties, Radiological Sciences, and Public Health, ASST Spedali Civili of Brescia, University of Brescia, Brescia, Italy.
Tito PoliMaxillo-Facial Surgery Division, Head and Neck Department, University Hospital of Parma, Parma, Italy.
Lisa LicitraHead and Neck Medical Oncology Department, Fondazione IRCCS, Istituto Nazionale dei Tumori, Milan, Italy.
Valentina CorinoDepartment of Electronics, Information and Bioengineering, Politecnico di Milano, Milan, Italy.
Luca MainardiDepartment of Electronics, Information and Bioengineering, Politecnico di Milano, Milan, Italy.
Fondazione IRCCS Istituto Nazionale dei Tumori · ITPolitecnico di Milano · ITUniversity of Brescia · ITVrije Universiteit Amsterdam · NLDutch Cancer Society · NLUniversity of Parma · IT

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

background. At present, the prognostic prediction in advanced oral cavity squamous cell carcinoma (OCSCC) is based on the tumor-node-metastasis (TNM) staging system, and the most used imaging modality in these patients is magnetic resonance image (MRI). With the aim to improve the prediction, we developed an MRI-based radiomic signature as a prognostic marker for overall survival (OS) in OCSCC patients and compared it with published gene expression signatures for prognosis of OS in head and neck cancer patients, replicated herein on our OCSCC dataset.

methodsFor each patient, 1072 radiomic features were extracted from T1 and T2-weighted MRI (T1w and T2w). Features selection was performed, and an optimal set of five of them was used to fit a Cox proportional hazard regression model for OS. The radiomic signature was developed on a multi-centric locally advanced OCSCC retrospective dataset (n = 123) and validated on a prospective cohort (n = 108).

resultsThe performance of the signature was evaluated in terms of C-index (0.68 (IQR 0.66-0.70)), hazard ratio (HR 2.64 (95% CI 1.62-4.31)), and high/low risk group stratification (log-rank p < 0.001, Kaplan-Meier curves). When tested on a multi-centric prospective cohort (n = 108), the signature had a C-index of 0.62 (IQR 0.58-0.64) and outperformed the clinical and pathologic TNM stage and six out of seven gene expression prognostic signatures. In addition, the significant difference of the radiomic signature between stages III and IVa/b in patients receiving surgery suggests a potential association of MRI features with the pathologic stage.

conclusionsOverall, the present study suggests that MRI signatures, containing non-invasive and cost-effective remarkable information, could be exploited as prognostic tools.

Indexed as

Head and neck cancerMagnetic resonance imagingOral cavity squamous cell carcinomaOverall survivalRadiogenomicsRadiomicsSurvival models

Identifiers

PMID37455307
PMCPMC10350277
OpenAlexW4384470768

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.